Emerging Therapies in Refractory Systemic Lupus Erythematosus: Efficacy and Safety of CAR-T Cell Therapy and FcRn Blockade – A Systematic Review and Meta-Analysis
Doctors often struggle to manage refractory systemic lupus erythematosus (SLE). Patients with this condition do not respond well to standard treatments. Researchers now explore new options like CAR-T cell therapy and FcRn blockade. These approaches bring hope for better disease control.
First, experts conducted a systematic review of recent studies. They searched major databases up to 2026. In total, they analyzed data from multiple trials and cohorts. This process helped them evaluate real-world outcomes. Moreover, they focused on patients who had failed several prior therapies.
CAR-T cell therapy targets specific immune cells. It uses engineered T cells to attack B cells that drive autoimmunity. In pooled analyses of around 47 to 98 patients across various studies, researchers noted strong results. For instance, about 81% of patients reached a low disease activity state. In addition, disease activity scores dropped sharply. The mean SLEDAI score fell from roughly 12.8 at baseline to 2.3 after six months. Many patients achieved full remission and stopped other immunosuppressive drugs. Furthermore, B cell depletion occurred quickly, and immune recovery followed over time.
Safety remains a key concern with any new treatment. However, CAR-T therapy showed manageable side effects in SLE patients. Cytokine release syndrome affected many individuals, yet most cases stayed mild (grades 1-2). Only a few patients experienced neurotoxicity, and those events were also mild. Infections occurred in some cases, but severe ones were limited. Overall, the therapy proved tolerable compared to its use in cancer. Long-term follow-up in select groups even reached four years with sustained remission and no major late complications.
Next, FcRn blockade offers another promising path. This method lowers harmful IgG autoantibodies without broad immune suppression. Nipocalimab, a leading FcRn inhibitor, demonstrated clear benefits in phase 2 trials. In the JASMINE-SLE study, patients on the higher dose achieved better SRI-4 response rates than those on placebo. These improvements continued through 52 weeks. Additionally, more patients reached low disease activity states, especially those with high autoantibodies or specific biomarkers. Researchers observed increases in complement levels and reductions in disease activity markers.
Safety data for FcRn blockade also looks favorable. Common side effects included mild issues like headaches or infections. Serious adverse events stayed low and comparable to placebo. Importantly, no new safety signals emerged during extended follow-up. This profile supports further development in moderate-to-severe SLE.
Both therapies differ in their mechanisms and applications. CAR-T therapy often provides deep, drug-free remission after a single infusion. In contrast, FcRn blockade works through ongoing antibody reduction and suits repeated dosing. Transitioning between these options could help tailor care to individual needs. Moreover, patient selection matters. Those with refractory disease and specific biomarkers respond best.
Nevertheless, limitations exist in the current evidence. Most studies involve small sample sizes and short follow-ups. Heterogeneity across trials makes direct comparisons challenging. Therefore, larger randomized controlled trials are essential. These studies should track long-term efficacy, safety, and quality of life. In addition, researchers need to explore combinations with existing treatments.
In conclusion, CAR-T cell therapy and FcRn blockade represent major advances for refractory SLE. They deliver meaningful improvements in disease control and safety. As research progresses, these therapies may transform patient outcomes. Clinicians should monitor new data closely. Future work will refine their roles and expand access for those in need.